Page 8 - MRS Abstracts March 2023

32 (31%) patients received a recommendation for Romosozumab. 8 patients were treated with Romosozumab. Others received Zoledronate (12), Denosumab (2), Alendronate (2) and Teriparatide (1). Romosozumab was not commenced in these 17 patients due to “clinician decline” [concern about cardiovascular risk (4), no convincing fracture within 24 months (2), further investigation required (1)] or “patient decline” [concern about cardiovascular risk (5), concern about self-injection (3), personal preference (2)]. 3 patients declined treatment with any osteoporosis medication, 3 are considering their treatment decision and 1 patient is pending review.
Conclusions:
The vertebral fracture pathway has improved rapid access to Romosozumab. 69% of patients discussed in MDT were not eligible for Romosozumab. However, the pathway was still beneficial as it resulted in fast-tracking to alternative treatment strategies.
Key points:
In our single-centre experience a fast-track vertebral fracture pathway is effective in aiding the prioritisation of Romosozumab. However, to operate effectively, it requires dedicated staff and protected clinic time.